These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16750687)

  • 1. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
    Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
    J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.
    Tsimikas S; Witztum JL
    Curr Opin Lipidol; 2008 Aug; 19(4):369-77. PubMed ID: 18607184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
    Tsimikas S; Tsironis LD; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
    Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
    Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
    J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.
    Juonala M; Viikari JS; Kähönen M; Solakivi T; Helenius H; Jula A; Marniemi J; Taittonen L; Laitinen T; Nikkari T; Raitakari OT
    J Am Coll Cardiol; 2008 Jul; 52(4):293-9. PubMed ID: 18634985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
    Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
    J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
    Tsimikas S; Duff GW; Berger PB; Rogus J; Huttner K; Clopton P; Brilakis E; Kornman KS; Witztum JL
    J Am Coll Cardiol; 2014 May; 63(17):1724-34. PubMed ID: 24530664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression.
    Tsimikas S; Aikawa M; Miller FJ; Miller ER; Torzewski M; Lentz SR; Bergmark C; Heistad DD; Libby P; Witztum JL
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):175-81. PubMed ID: 17082490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.
    Fefer P; Tsimikas S; Segev A; Sparkes J; Otsuka F; Kolodgie F; Virmani R; Juliano J; Charron T; Strauss BH
    Cardiovasc Revasc Med; 2012; 13(1):11-9. PubMed ID: 22079685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.